Guggenheim Capital LLC Boosts Stake in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Guggenheim Capital LLC grew its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 35.4% during the first quarter, according to its most recent filing with the SEC. The firm owned 22,811 shares of the medical equipment provider’s stock after acquiring an additional 5,962 shares during the period. Guggenheim Capital LLC’s holdings in Lantheus were worth $1,883,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in LNTH. National Bank of Canada FI grew its holdings in shares of Lantheus by 35.7% during the 1st quarter. National Bank of Canada FI now owns 445 shares of the medical equipment provider’s stock worth $37,000 after acquiring an additional 117 shares during the period. AlphaMark Advisors LLC grew its stake in shares of Lantheus by 456.3% in the 1st quarter. AlphaMark Advisors LLC now owns 445 shares of the medical equipment provider’s stock worth $37,000 after buying an additional 365 shares during the last quarter. Coppell Advisory Solutions Corp. purchased a new stake in shares of Lantheus in the 4th quarter worth approximately $48,000. Clearstead Advisors LLC purchased a new stake in shares of Lantheus in the 1st quarter worth approximately $52,000. Finally, Globeflex Capital L P grew its stake in shares of Lantheus by 10,600.0% in the 4th quarter. Globeflex Capital L P now owns 1,070 shares of the medical equipment provider’s stock worth $55,000 after buying an additional 1,060 shares during the last quarter. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Insider Activity

In other news, President Paul Blanchfield sold 408 shares of the stock in a transaction on Monday, August 21st. The stock was sold at an average price of $66.10, for a total transaction of $26,968.80. Following the transaction, the president now directly owns 90,067 shares of the company’s stock, valued at approximately $5,953,428.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In related news, CAO Andrea Sabens sold 1,752 shares of the firm’s stock in a transaction on Wednesday, July 19th. The stock was sold at an average price of $90.87, for a total value of $159,204.24. Following the transaction, the chief accounting officer now directly owns 59,767 shares of the company’s stock, valued at approximately $5,431,027.29. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, President Paul Blanchfield sold 408 shares of the firm’s stock in a transaction on Monday, August 21st. The stock was sold at an average price of $66.10, for a total value of $26,968.80. Following the completion of the transaction, the president now directly owns 90,067 shares in the company, valued at $5,953,428.70. The disclosure for this sale can be found here. Insiders have sold 19,315 shares of company stock valued at $1,353,773 in the last ninety days. 1.50% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several analysts recently weighed in on the company. SVB Securities upped their price target on Lantheus from $120.00 to $127.00 in a research note on Friday, May 5th. StockNews.com assumed coverage on Lantheus in a research note on Thursday, August 17th. They issued a “buy” rating on the stock. JMP Securities upped their price target on Lantheus from $120.00 to $130.00 in a research note on Friday, May 5th. TheStreet upgraded Lantheus from a “c” rating to a “b-” rating in a research note on Wednesday, August 9th. Finally, Mizuho upped their price objective on Lantheus from $115.00 to $125.00 in a research report on Friday, May 5th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $121.83.

Lantheus Stock Performance

LNTH stock opened at $67.79 on Thursday. The stock has a market capitalization of $4.64 billion, a PE ratio of 165.34 and a beta of 0.65. Lantheus Holdings, Inc. has a 12-month low of $47.46 and a 12-month high of $100.85. The company has a current ratio of 4.88, a quick ratio of 4.55 and a debt-to-equity ratio of 1.01. The stock’s 50 day simple moving average is $79.05 and its 200 day simple moving average is $81.73.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings results on Thursday, August 3rd. The medical equipment provider reported $1.40 earnings per share for the quarter, beating the consensus estimate of $1.23 by $0.17. The firm had revenue of $321.70 million for the quarter, compared to analysts’ expectations of $306.48 million. Lantheus had a return on equity of 67.18% and a net margin of 2.97%. As a group, research analysts forecast that Lantheus Holdings, Inc. will post 5.19 earnings per share for the current fiscal year.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; and Cardiolite, an injectable Tc-99m-labeled imaging agent.